Your browser does not support JavaScript! CLINDAMYCIN PHOSPHATE SOLUTION CLINDAMYCIN PHOSPHATE LOTION CLINDAMYCIN PHOSPHATE GEL [GREENSTONE LLC]
DailyMed Logo Header image

Daily Med

Current Medication Information

Options

RxNorm Names

CLINDAMYCIN PHOSPHATE solution
CLINDAMYCIN PHOSPHATE lotion
CLINDAMYCIN PHOSPHATE gel
[Greenstone LLC]


Category DEA Schedule Marketing Status
HUMAN PRESCRIPTION DRUG LABEL New Drug Application Authorized Generic
Drug Label Sections

For External Use

DESCRIPTION

Clindamycin phosphate topical solution and clindamycin phosphate topical lotion contain clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per milliliter. Clindamycin phosphate topical gel contains clindamycin phosphate, USP, at a concentration equivalent to 10 mg clindamycin per gram. Each clindamycin phosphate topical solution pledget applicator contains approximately 1 mL of topical solution.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

The solution contains isopropyl alcohol 50% v/v, propylene glycol, and water.

The gel contains allantoin, carbomer 934P, methylparaben, polyethylene glycol 400, propylene glycol, sodium hydroxide, and purified water.

The lotion contains cetostearyl alcohol (2.5%); glycerin; glyceryl stearate SE (with potassium monostearate); isostearyl alcohol (2.5%); methylparaben (0.3%); sodium lauroyl sarcosinate; stearic acid; and purified water.

The structural formula is represented below:

Chemical Structure

The chemical name for clindamycin phosphate is Methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-trans-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-threo-α-D-galacto-octopyranoside 2-(dihydrogen phosphate).

CLINICAL PHARMACOLOGY

Although clindamycin phosphate is inactive in vitro, rapid in vivo hydrolysis converts this compound to the antibacterially active clindamycin.

Cross resistance has been demonstrated between clindamycin and lincomycin.

Antagonism has been demonstrated between clindamycin and erythromycin.

Following multiple topical applications of clindamycin phosphate at a concentration equivalent to 10 mg clindamycin per mL in an isopropyl alcohol and water solution, very low levels of clindamycin are present in the serum (0–3 ng/mL) and less than 0.2% of the dose is recovered in urine as clindamycin.

Clindamycin activity has been demonstrated in comedones from acne patients. The mean concentration of antibiotic activity in extracted comedones after application of clindamycin phosphate topical solution for 4 weeks was 597 mcg/g of comedonal material (range 0–1490). Clindamycin in vitro inhibits all Propionibacterium acnes cultures tested (MICs 0.4 mcg/mL). Free fatty acids on the skin surface have been decreased from approximately 14% to 2% following application of clindamycin.

INDICATIONS AND USAGE

Clindamycin phosphate topical solution, clindamycin phosphate topical gel and clindamycin phosphate topical lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS, WARNINGS and ADVERSE REACTIONS.)

CONTRAINDICATIONS

Clindamycin phosphate topical solution, clindamycin phosphate topical gel and clindamycin phosphate topical lotion are contraindicated in individuals with a history of hypersensitivity to preparations containing clindamycin or lincomycin, a history of regional enteritis or ulcerative colitis, or a history of antibiotic-associated colitis.

WARNINGS

Orally and parenterally administered clindamycin has been associated with severe colitis which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.

Studies indicate a toxin(s) produced by clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Endoscopic examination may reveal pseudomembranous colitis. Stool culture for Clostridium difficile and stool assay for C. difficile toxin may be helpful diagnostically.

When significant diarrhea occurs, the drug should be discontinued. Large bowel endoscopy should be considered to establish a definitive diagnosis in cases of severe diarrhea.

Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen the condition. Vancomycin has been found to be effective in the treatment of antibiotic-associated pseudomembranous colitis produced by Clostridium difficile. The usual adult dosage is 500 milligrams to 2 grams of vancomycin orally per day in three to four divided doses administered for 7 to 10 days. Cholestyramine or colestipol resins bind vancomycin in vitro. If both a resin and vancomycin are to be administered concurrently, it may be advisable to separate the time of administration of each drug.

Diarrhea, colitis, and pseudomembranous colitis have been observed to begin up to several weeks following cessation of oral and parenteral therapy with clindamycin.

PRECAUTIONS

General

Clindamycin phosphate topical solution contains an alcohol base which will cause burning and irritation of the eye. In the event of accidental contact with sensitive surfaces (eye, abraded skin, mucous membranes), bathe with copious amounts of cool tap water. The solution has an unpleasant taste and caution should be exercised when applying medication around the mouth.

Clindamycin phosphate topical products should be prescribed with caution in atopic individuals.

Drug Interactions

Clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore it should be used with caution in patients receiving such agents.

Pregnancy

Teratogenic effects—Pregnancy Category B

Oral and subcutaneous reproductive toxicity studies in rats and rabbits revealed no evidence of impaired fertility or harm to the fetus due to clindamycin, except at doses that caused maternal toxicity. Animal reproduction studies are not always predictive of human response.

In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.

Clindamycin should be used during the first trimester of pregnancy only if clearly needed. There are no adequate and well-controlled studies in pregnant women during the first trimester of pregnancy.

Nursing Mothers

It is not known whether clindamycin is excreted in human milk following use of clindamycin phosphate. However, orally and parenterally administered clindamycin has been reported to appear in breast milk. Because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients under the age of 12 have not been established.

Geriatric Use

Clinical studies for Cleocin T did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

In 18 clinical studies of various formulations of clindamycin phosphate using placebo vehicle and/or active comparator drugs as controls, patients experienced a number of treatment emergent adverse dermatologic events [see table below].

Number of Patients Reporting Events
Treatment Emergent
Adverse Event
Solution
n=553(%)
Gel
n=148(%)
Lotion
n=160(%)
# not recorded
*
of 126 subjects
Burning62 (11)15 (10)17 (11)
Itching36 ( 7)15 (10)17 (11)
Burning/Itching60 (11)# (−)# (−)
Dryness105 (19)34 (23)29 (18)
Erythema86 (16)10 ( 7)22 (14)
Oiliness/Oily Skin8 ( 1)26 (18)12* (10)
Peeling61 (11)# (−)11 ( 7)

Orally and parenterally administered clindamycin has been associated with severe colitis which may end fatally.

Cases of diarrhea, bloody diarrhea and colitis (including pseudomembranous colitis) have been reported as adverse reactions in patients treated with oral and parenteral formulations of clindamycin and rarely with topical clindamycin (see WARNINGS).

Abdominal pain and gastrointestinal disturbances as well as gram-negative folliculitis have also been reported in association with the use of topical formulations of clindamycin.

OVERDOSAGE

Topically applied clindamycin phosphate can be absorbed in sufficient amounts to produce systemic effects. (See WARNINGS.)

DOSAGE AND ADMINISTRATION

Apply a thin film of clindamycin phosphate topical solution, clindamycin phosphate topical lotion, clindamycin phosphate topical gel, or use a clindamycin phosphate topical solution pledget for the application of clindamycin phosphate twice daily to affected area. More than one pledget may be used. Each pledget should be used only once and then be discarded.

Lotion: Shake well immediately before using.

Pledget: Remove pledget from foil just before use. Do not use if the seal is broken. Discard after single use.

Keep all liquid dosage forms in containers tightly closed.

HOW SUPPLIED

Clindamycin phosphate topical solution containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following sizes:

30 mL applicator bottle—NDC 59762-3728-1

60 mL applicator bottle—NDC 59762-3728-2

Carton of 60 single-use pledget applicators—NDC 59762-3728-3

Clindamycin phosphate topical gel containing clindamycin phosphate equivalent to 10 mg clindamycin per gram is available in the following sizes:

30 gram tube—NDC 59762-3743-1

60 gram tube—NDC 59762-3743-2

Clindamycin phosphate topical lotion containing clindamycin phosphate equivalent to 10 mg clindamycin per milliliter is available in the following size:

60 mL plastic squeeze bottle—NDC 59762-3744-1

Store at controlled room temperature 20° to 25°C (68° to 77°F) [see USP].

Protect from freezing.

Rx only

Logo

LAB-0048-6.0
December 2013

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Solution

NDC 59762-3728-2
60 mL

GREENSTONE® BRAND

clindamycin
phosphate
topical
solution, USP

1%*

Solution for topical use
only

Rx only

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Solution

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Solution

NDC 59762-3728-2
60 mL

GREENSTONE® BRAND

clindamycin
phosphate
topical
solution, USP

1%*

Solution for topical use
only

Rx only

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Solution

PRINCIPAL DISPLAY PANEL - Pledget Packet

NDC 59762-3728-3
1 Pledget

GREENSTONE® BRAND

clindamycin
phosphate
topical
solution, USP

1%*

Pledget for topical use only

Rx only

PRINCIPAL DISPLAY PANEL - Pledget Packet

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Lotion

NDC 59762-3744-1
60 mL

GREENSTONE® BRAND

clindamycin
phosphate
topical lotion

1%*

For topical use
only

Rx only

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label - Lotion

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Lotion

NDC 59762-3744-1
60 mL

GREENSTONE® BRAND

clindamycin
phosphate
topical
lotion

1%*

For topical use only

Rx only

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Carton - Lotion

PRINCIPAL DISPLAY PANEL - 60 gram Tube Label

NDC 59762-3743-2
60 gram

GREENSTONE® BRAND

clindamycin phosphate
topical gel

1%*

For topical use only

Rx only

Store at controlled room temperature 20° to 25°C (68° to 77°F)
[see USP]. Protect from freezing.

For external use only. Avoid contact with eyes.

See crimp of tube for Expiration Date and Lot Number.

DOSAGE AND USE: See accompanying prescribing information.

*Each gram contains clindamycin phosphate equivalent to 10 mg
(1%) of clindamycin. Also contains allantoin, carbomer 934P,
methylparaben, polyethylene glycol 400, propylene glycol, sodium
hydroxide, and purified water.

G
Distributed by:
Greenstone LLC, Peapack, NJ 07977

PRINCIPAL DISPLAY PANEL - 60 gram Tube Label

PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton

NDC 59762-3743-2
60 gram

GREENSTONE® BRAND

clindamycin phosphate topical gel

1%*

For topical use only

Rx only

PRINCIPAL DISPLAY PANEL - 60 gram Tube Carton
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate solution
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:59762-3728
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
ISOPROPYL ALCOHOL 
PROPYLENE GLYCOL 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:59762-3728-11 in 1 CARTON
130 mL in 1 BOTTLE
2NDC:59762-3728-21 in 1 CARTON
260 mL in 1 BOTTLE
3NDC:59762-3728-360 in 1 CARTON
31 mL in 1 PACKET
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDA AUTHORIZED GENERICNDA05053706/20/1980
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate lotion
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:59762-3744
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 mL
Inactive Ingredients
Ingredient NameStrength
CETOSTEARYL ALCOHOL 
GLYCERIN 
ISOSTEARYL ALCOHOL 
METHYLPARABEN 
SODIUM LAUROYL SARCOSINATE 
STEARIC ACID 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:59762-3744-11 in 1 CARTON
160 mL in 1 BOTTLE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDA AUTHORIZED GENERICNDA05060005/31/1989
CLINDAMYCIN PHOSPHATE 
clindamycin phosphate gel
Product Information
Product TypeHUMAN PRESCRIPTION DRUG LABELItem Code (Source)NDC:59762-3743
Route of AdministrationTOPICALDEA Schedule    
Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
CLINDAMYCIN PHOSPHATE (CLINDAMYCIN) CLINDAMYCIN10 mg  in 1 g
Inactive Ingredients
Ingredient NameStrength
ALLANTOIN 
CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) 
METHYLPARABEN 
POLYETHYLENE GLYCOL 400 
PROPYLENE GLYCOL 
SODIUM HYDROXIDE 
WATER 
Packaging
#Item CodePackage DescriptionMarketing Start DateMarketing End Date
1NDC:59762-3743-11 in 1 CARTON
130 g in 1 TUBE
2NDC:59762-3743-21 in 1 CARTON
260 g in 1 TUBE
Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
NDA AUTHORIZED GENERICNDA05061501/07/1987
Labeler - Greenstone LLC (825560733)
Registrant - Pfizer Inc (113480771)
Establishment
NameAddressID/FEIBusiness Operations
Chongqing Carelife Pharmaceutical Co., Ltd531132009API MANUFACTURE(59762-3743, 59762-3744, 59762-3728)
Establishment
NameAddressID/FEIBusiness Operations
Zhejiang Hisoar Pharmaceutical Co., Ltd.530736917API MANUFACTURE(59762-3743)
Establishment
NameAddressID/FEIBusiness Operations
Pharmacia and Upjohn Company829076566ANALYSIS(59762-3743, 59762-3744, 59762-3728), API MANUFACTURE(59762-3743, 59762-3744, 59762-3728), LABEL(59762-3743, 59762-3744, 59762-3728), MANUFACTURE(59762-3743, 59762-3744, 59762-3728), PACK(59762-3743, 59762-3744, 59762-3728)

Revised: 12/2013
 
Greenstone LLC

Visit The National Library of Medicine Copyright, Privacy, Accessibility
U.S. National Library of Medicine, 8600 Rockville Pike, Bethesda, MD 20894
National Institutes of Health, Health & Human Services